1 Original Article

- 2 Title page
- 3
- 4 Title: Assessing the Role of Red Blood Cell Distribution Width in Hospital Mortality
- 5 Among Elderly and Non-Elderly COVID-19 Patients: A Prospective Study in a
- 6 Brazilian University Hospital
- 7
- 8 Short Title: RDW and COVID-19 mortality
- 9
- 10 Helena <u>Duani</u>^{1,2,4}
- 11 Máderson Alvares de Souza <u>Cabral^{1,2}</u>
- 12 Carla Jorge Machado³
- 13 Thalyta Nogueira Fonseca²
- 14 Milena Soriano <u>Marcolino^{1,4}</u>
- 15 Vandack Alencar <u>Nobre</u> Jr.^{1,4}
- 16 Cecilia Gómez Ravetti⁴
- 17 Paula Frizera Vassallo⁵
- 18 Unaí <u>Tupinambás</u>^{1,2,4}
- 19
- ¹Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical,
 Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
- ²Serviço de Doenças Infecciosas e Parasitárias, Hospital das Clínicas, Universidade
 Federal de Minas Gerais, Belo Horizonte, Brazil.
- ³Programa de Pós Graduação em Promoção de Saúde e Prevenção da Violência,
 Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
- ⁴Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas
 Gerais, Belo Horizonte, Brazil.
- ⁵Unidade de Terapia Intensiva Adulto, Hospital das Clínicas, Universidade Federal de
 Minas Gerais, Belo Horizonte, Brazil.

30

31 Corresponding Author:

- 33 NHElenarphilineports how research that has not been certified by peer review and should not be used to guide clinical practice.
 34 Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina
- 35 Tropical, Serviço de Infectologia, Faculdade de Medicina, Universidade Federal
- 36 de Minas Gerais, UFMG.
- 37 Avenida Professor Alfredo Balena 190, room #503, Belo Horizonte, Minas
- 38 Gerais,

- 39 Brazil. CEP: 30130-100
- 40 Telephone: (+55 31) 33079383
- 41 Cell phone: (+55 31) 983056583
- 42 e-mail: duani@ufmg.br
- alternative e-mail: hduani@gmail.com 43 44
- 45 ORCID:
- 46
- 47 Helena Duani: https://orcid.org/0000-0001-9345-018X
- 48 Máderson Alvares de Souza Cabral: https://orcid.org/0000-0001-8556-1998
- 49 Carla Jorge Machado: https://orcid.org/0000-0002-6871-0709
- 50 Thalyta Nogueira Fonseca: https://orcid.org/0000-0003-2319-6520
- 51 Milena Soriano Marcolino: https://orcid.org/0000-0003-4278-3771
- 52 Vandack Alencar Nobre Jr.: https://orcid.org/0000-0002-7922-0422
- 53 Cecilia Gómez Ravetti: https://orcid.org/0000-0002-6349-3063
- Paula Frizera Vassallo: https://orcid.org/0000-0002-7531-0607 54
- 55 Unaí Tupinambás: https://orcid.org/0000-0001-6833-3870
- 56
- 57

3

59 Summary

This study investigated the role of red blood cell distribution width (RDW) as a risk 60 61 factor for hospital mortality in COVID-19 patients at a public hospital in Minas 62 Gerais, Brazil. The study included 161 patients over 16 years old hospitalized between May and October 2020, with 39 (24.2%) deaths. Key mortality risk factors 63 64 identified were age over 70 years (RR=2.78; p<0.001), male sex (RR=2.28; 65 p=0.005), cardiovascular disease (RR=1.8; p=0.044), and abnormal chest X-ray 66 upon admission (RR=3.07; p=0.022). Although high RDW at admission did not 67 significantly predict mortality (31.1% vs 21.7%; RR=1.43; p=0.413), it was linked to 68 higher mortality in patients aged 70 and over (66.7% vs 33.3%; RR=2; p=0.029). 69 High RDW during hospitalization was a strong mortality factor for the entire cohort 70 (41.1% vs 10.2%; RR=4.03; p<0.001) and at any time during the stay (39.7% vs 71 9.6%; RR=4.14; p<0.001). The Cox model analysis showed that age >70 years 72 (HR=4.8; p<0.001), white race (HR=3.2; p=0.018), need for invasive ventilation 73 (HR=3.8; p=0.001), and abnormal chest X-ray (HR=3.5; p=0.044) were significant 74 risk factors, but RDW was not associated with mortality.

75

76 Keywords: COVID-19, RDW, mortality, SARS-CoV-2, biomarkers.

78 Introduction

79

80 In December 2019, an outbreak of atypical cases of viral pneumonia, henceforth 81 referred to as COVID-19, was reported in Wuhan, China. A few weeks later, a new 82 beta-coronavirus - the severe acute respiratory syndrome coronavirus 2 (SARS-83 CoV-2) – was established as the etiologic agent of this disease. COVID-19 quickly 84 spread throughout the globe and was classified as a pandemic by the World Health 85 Organization in March 2020 [1].

86 The spectrum of clinical presentation of COVID-19 is broad, varying from 87 asymptomatic infection to severe and critical disease. Patients with old age and 88 comorbidities, such as heart, lung, or kidney disease; hypertension; diabetes; 89 cancer; smoking; and obesity have a higher risk for severe disease and mortality.

90 [2-7]

91 Many researchers are interested in identifying circulating biomarkers able to select 92 patients with a higher risk of unfavorable clinical outcomes and death. In this 93 context, some studies have shown that high D-dimer levels, lymphocytopenia [3,8], 94 and some higher red blood cell distribution widths (RDW) are associated with poor 95 outcomes [9]. Froy et al. concluded that patients with COVID-19 that presented with 96 a high RDW upon hospital admission and an increasing RDW during hospitalization 97 presented a higher risk of mortality [9].

Thus, the present study aimed to investigate, in a Brazilian sample of COVID-19 98 99 patients admitted to a public university hospital, if RDW measured upon admission 100 or during hospitalization is associated with hospital mortality.

101

102 Material and Methods

103

This study included all patients aged \geq 16 years who had been admitted between 104

5

105 May 1 and October 31, 2020 to the Hospital das Clínicas of the Universidade 106 Federal de Minas Gerais (HC-UFMG), in Belo Horizonte, Brazil, with Severe Acute 107 Respiratory Syndrome (SARS) or clinical symptoms whose evolution led to the 108 suspicion of COVID-19 within the first three weeks of hospitalization. Patients 109 hospitalized for other pathologies who became infected with COVID-19 during 110 hospitalization were not included. Belo Horizonte, the capital city of the Southeast 111 region of Brazil, has a population of over 2 million people. Among these residents, 112 more than 80,000 are aged between 70 and 74 years old, highlighting a significant 113 elderly demographic within the city (https://cidades.ibge.gov.br/brasil/mg/belo-114 horizonte/panorama, assessed in July 11, 2024.

115

The HC-UFMG is a university hospital with more than 400 beds and is a regional reference for the treatment of high complexity cases, including organ transplants and neoplasms. Since the onset of the COVID-19 pandemic, the hospital has been a part of the Brazilian Unified Health System (SUS) for the treatment of suspected cases in the metropolitan area of Belo Horizonte, Brazil.

Patients were followed up by the study team through a daily active search. Data
were collected prospectively based on the hospital's electronic medical records
and radiological and laboratory examination information systems.

124

A confirmed case of COVID-19 was defined as patients with a positive real-time polymerase chain reaction (RT-PCR) for the detection of SARS-CoV-2 in tracheal aspirate or naso-oropharyngeal swab. Cases with clinical suspicion and radiological findings but without laboratory confirmation were not included.

129

A questionnaire was filled out during the study team's follow-up to obtain the
variables to be studied and compiled in a database. The race/color variable was
obtained by self-declaration.

6

133

134 The duration of symptoms reported in the first medical record was considered. 135 Comorbidities reported in medical records were recorded and categorized. 136 defined Immunosuppression was as the presence of neoplasia, an 137 immunosuppressive hematologic condition, primary or acquired immunodeficiency, 138 a relevant clinical condition whose treatment involves the use of or 139 immunosuppressants or high-dose of corticosteroids. The first chest X-ray or 140 computed tomography (CT) scan performed during hospitalization was considered. 141 X-rays were considered suggestive if bilateral diffuse interstitial infiltrate was found 142 in an independent review by two physicians (in case of disagreement, a third 143 physician reviewed the exam for a definitive opinion) and CT findings were taken 144 from an official report prepared by a radiologist.

145

146 All laboratory tests were performed according to clinical indication, following the 147 institution's protocol for the treatment of suspected COVID-19 cases. The 148 admission blood count was defined as the first blood count test performed within 149 24 hours of admission. For this test, the values of the RDW, total leukocytes, 150 lymphocytes, neutrophils, mean corpuscular volume (MCV), and platelets were 151 analyzed as continuous variables and categorized as low, normal, or high (in 152 relation to standardized reference values in the service laboratory). The RDW was 153 also categorized as normal (no changes during hospitalization) or high (value 154 above the upper limit of normality at some point during hospitalization).

155

156 This research was conducted in accordance with the ethical principles established 157 in the Declaration of Helsinki. The study protocol was reviewed and approved by 158 the Institutional Review Board of UFMG, under the approval number 159 30437020.9.3001.5124. All participants were informed about the study's objectives, 160 procedures, potential risks, and benefits, and they signed a written informed

7

161 consent form prior to participation.

162

163 Statistical Analysis

164

After categorizing the variables, an analysis stratified by survival or death, was performed using mean and standard deviation for continuous variables, with normal distribution, and absolute numbers and percentages for categorical variables. The adopted significance level was 5% (p<0.05).

169

170 For data stratified into normal RDW and high RDW groups, the percentage of 171 deaths within these groups was calculated and compared across two selected age 172 categories (<70 years and \geq 70 years). The rationale for using 70 years as the age criterion was to investigate potential differences in RDW-related outcomes across 173 174 age groups. This threshold is commonly employed in clinical studies to distinguish 175 between younger and older populations, considering the physiological and clinical 176 changes that occur with aging. Additionally, 72 years is recognized as the global 177 life expectancy [10]. Other studies on COVID-19 mortality and comorbidities have 178 shown that individuals aged 70 years or older are more likely to have underlying 179 health conditions and, therefore, a higher risk of mortality [11].

180

Subsequently, the Gross and Mantel-Haenszel-adjusted risk ratios were calculated to assess the association between RDW levels and mortality risk. The same analytical procedure was applied to data stratified based on RDW upon admission (normal RDW upon admission vs. high RDW upon admission). A significance level of 5% (p<0.05) was adopted for all statistical tests.

186

187 Next, for the data stratified into normal RDW and high RDW, the percentage of

8

deaths in these groups was calculated, which was then compared within two selected age groups (<70 years and 70 years or more), after which the Gross and Mantel-Haenszel-adjusted risk ratio was calculated. The same procedure was also used for data stratified into normal RDW upon admission and high RDW upon admission. The adopted significance level was 5% (p<0.05).</p>

193

194 A time-to-death analysis was performed for variables that proved to be significant 195 (p<0.05) in the comparison between people who survived and died using the Cox 196 proportional hazards model in univariate regression analysis. Those variables that 197 revealed a significance level equal to or less than 20% (p<0.20) formed the basis 198 of an initial multivariate model, and only those with a significance level equal to or 199 greater than 5% remained in this model (p<0.05). Finally, Kaplan Meier survival 200 curves for the variables in the final model were estimated to obtain a better graphic 201 visualization of the differences between the categories in time until death.

202

203 Results

204

205 Among the 169 patients with laboratory confirmations of COVID-19 who were 206 hospitalized during the study period, 161 patients were included, of which 145 (90.1%) were directly admitted to respiratory isolation with SARS and 16 (9.9%) 207 208 were admitted with nonspecific symptoms that led to the suspicion of COVID-19 209 after an average of 6.6 (1 to 18) days. Eight patients with detectable RT-PCR were 210 not included because they were suspected cases of healthcare-associated COVID-211 19 infection, it means that the patient acquired the virus inside the hospital, we not 212 exclude another bacterial or fungal healthcare infections. The main characteristics 213 presented by the patients included in the study are shown in Table 1. Of the 161 214 patients included, 39 (24.2%) died during hospitalization, 32 of them within the first 215 30 days, resulting in a 30-day mortality of 19.9%.

9

Eighty patients (49.7%) were male and 147 (91.3%) were self-declared black (black
or brown). Mortality was 14.8% among women and 33.8% among men, this
difference being statistically significant (RR=2.28; p=0.005). There was no
difference in mortality rates between whites and blacks (42.7% vs 22.5%; RR=1.9;
p=0.089).

The mean age was 60.1 years (17 to 93, standard deviation - SD 16.9), with a median of 63 years. The mean age among survivors was 56.9 (16.7) years, while it was 70.3 (13.3) years among non-survivors, with a statistically significant difference (p<0.001). In addition, patients over 70 years of age had a higher mortality rate (43.1% vs 15.5%; RR=2.78; p<0.001).

226

The mean time from symptoms to hospital admission was 6.1 days (standard deviation - SD - 4.6), with a median of 5 days. Patients had an average of 2.44 comorbidities (SD 1.4), the most common being systemic arterial hypertension (74; 46%) and solid or hematologic malignancy (41; 25.5%). Seventy-one patients (44.1%) were considered to have immunosuppression. Four patients were living with HIV. Only eight (5%) patients had no previous comorbidity, with 38 (23.6%) having one, 45 (27.9%) two, and 70 (43.5%) at least three comorbidities.

Among the most commonly reported comorbidities, the presence of chronic heart disease was a risk factor for mortality (37.1% vs 20.6%; RR=1.8; p=0.044). The presence of other comorbidities was not associated with mortality.

In this cohort, 62 patients (38.5%) developed a critical form of the disease and
required admission to intensive care, with 34 of them (54.8%) being admitted
directly to the Intensive Care Unit (ICU). The mean length of stay in ICU was 12.9
(14.3) days. Forty-one patients (25.5%) required invasive mechanical ventilation
(MV), with a mean length of stay of 15.5 (19.3) days.

242

As expected, the mortality rate was higher among patients who required intensive

10

244	care (51.6% vs 7.1%; RR= 7.26; p<0.001) and those who required mechanical
245	ventilation (73.2% vs 7.3%; RR=10.03; p< 0.001). However, there was no difference
246	in mortality rates between patients who were admitted directly to intensive care and
247	those who were admitted to the ward and later transferred to intensive care (47.1%
248	vs 57.1%; RR=0.82; p=0.429). Furthermore, among those who required such
249	interventions, there was no difference in the length of stay in intensive care (mean
250	13.6, SD 11.2 vs mean 12.2, SD 17.3; p=0.7194) or in the time of MV (mean 12.7,
251	SD 10.6 vs mean 23.1, SD 32.7; p=0.1275) between deaths and survivors.
252	
253	Imaging exams

254

255 One hundred and forty-four (89.4%) patients underwent at least one chest X-ray 256 during hospitalization, the first being analyzed in cases in which it was performed 257 more than once. COVID-19 was considered suggestive in 114 (79.2%) of these 258 patients based on an interpretation by two clinicians.

259 Computed tomography of the chest was performed in 110 (68.3%) of the patients, 260 on average 9.3 days after the onset of symptoms (SD 5.7), with the results being 261 compatible with COVID-19 in 81 cases (73.6%) in an official report prepared by a 262 radiologist. The most common findings were: ground glass opacities in 91 cases 263 (82.7%), which was diffuse with peripheral predominance in 81 cases (73.6%; 2 of 264 these patients also had ground glass opacities of bilateral central distribution) and 265 localized in 10 cases (9.1%); septal thickening in 62 cases (56.4%); consolidation 266 in 39 cases (35.5%); pleural effusion in 32 cases (29.1%); atelectasis in 28 cases 267 (25.5%); lymphadenopathy in 23 cases (20.9%); and mosaic paving in 20 cases 268 (18.2%).

269

A chest X-ray considered suggestive of COVID-19 was associated with a higher
mortality rate (30.7% vs 10%; RR=3.07; p=0.022). However, a chest CT that was

11

reported as compatible with COVID-19 did not represent an additional risk of
mortality (18.5% vs 9.5%; RR=1.95; p=0.512). Among the findings described in the
CT scan reports, the presence of a mosaic paving pattern was found to be a risk
factor for higher mortality (45% vs 11.1%; RR=4.05; p<0.001). No difference was
found in the time taken to perform a chest CT between survivors and deaths (mean
9.5, SD 5.7 vs mean 8.4, SD 5.9; p=0.4478).

278

279 Laboratory exams

280

Fifty-two patients underwent at least one D-dimer measurement at some point during hospitalization, with mean values of 2,708 (SD 4,797), which was categorized as normal in 7 (13.5%) and high in 45 (86.5%) patients.

No difference was found in the D-dimer value between survivors and non-survivors

285 (mean 2518, SD 4,063 vs mean 3418, SD 7,114; p=0.5857) and having a high D-

dimer was not a risk factor for mortality (22.2% vs 14.3%; RR=1.55; p=0.798).

All 161 patients underwent at least one blood count test during hospitalization. A total of 2,227 blood counts were taken, with a mean of 13.8 per patient (standard deviation 12.9), ranging from 1 to 84. The RDW upon admission was normal in 115 (71.4%), high in 45 (28%), and low in 1 (0.6%). The mean RDW values upon admission were 14.5 (SD 2.4), a value that is within the normal range.

292 Among patients with normal RDW upon admission, 82 (71.3%) remained normal 293 and 33 (28.7%) rose to high levels over time. Among those with high RDW upon 294 admission, 40 (88.9%) remained high and 5 (11.1%) returned to normal. The only 295 patient with low RDW upon admission returned to normal. When categorized, 88 296 (54.7%) had normal RDW and 73 (45.3%) had high RDW during the whole 297 hospitalization time. No difference was found in the mean RDW value upon 298 admission between survivors and non-survivors (14.4 [2.4] between survivors' vs 299 14.9 [2.4] between non-survivors; p=0.2081).

12

300

The risk for mortality in the group with high RDW upon admission was higher than in the group with normal RDW, but without statistical significance (31.1% vs 21.7%; RR=1.43; p=0.413). However, in the subgroup of patients \geq 70 years old, a statistical significance was observed in the mortality (66.7% for high RDW vs 33.3% for normal RDW; RR=2; p=0.029), Table 2.

306

Furthermore, when subsequent laboratory findings of progression (RDW evolution, Table 1) is categorized, there is a higher risk of mortality among those with high RDW after admission (41.1% vs 10.2%; RR=4.03; p<0.001). Moreover, when considering the RDW that changes at any time during hospitalization against such a normal parameter in all of the blood count results, a significant risk of mortality tends to be observed for the entire cohort (39.7% vs 9.6%; RR=4.14; p<0.001).

313

No significant difference was found in mortality between the different categories upon admission in relation to other parameters analyzed in the blood count, except for the absolute platelet counts between survivors and non-survivors (mean 216.3x10³, SD 110.7 vs mean 171.2x10³, SD 80; p=0.0198).

318

319 Survival analysis

In a univariate analysis using the Cox Model (Table 3), the risk factors for lower
survival were: male sex, HR 2.3 (1.1;4.5), p=0.018; age >70 years, HR 3.3 (1.7;6.5),
p<0.001; white race, HR 2.5 (1.0;6.1), p=0.039; need for invasive mechanical
ventilation, HR 4.9 (2.2;10.6), p<0.001; and need for intensive care admission, HR
3.7 (1.6;8.6), p=0.003.

325

13

327 We included the variables that were significant in the univariate analysis in our 328 multivariate model. Although RDW was not included because it was significant only 329 for a subset of the population (patients over 70 years), we aimed to develop a generalized model suitable for the diverse and complex patient population in our 330 331 cohort. The multivariate analysis was adjusted for variables that provided the best 332 model fit, enhancing its robustness despite the complexity of the cases studied. 333 When performing a multivariate analysis, the following continue to be risk factors 334 for lower survival: age >70 years, HR 4.8 (95% CI: 2.3;10.3), p<0.001; white race, 335 HR 3.2 (95% CI: 1.2; 8.61), p=0.018; and need for invasive MV, HR 3.8 (1.7;8.7), 336 p=0.001. The presence of a chest X-ray suggestive of COVID-19, HR 3.5 (95% CI: 337 1.0;11.5), p=0.044, also appears to be a risk factor in this analysis. Figure 1 shows 338 the Kaplan-Meier curves for the variables that presented a lower risk of survival in 339 the multivariate analysis.

340

Figure 1: Kaplan-Meier curves for survival estimates of COVID-19 patients in a public university hospital in Belo Horizonte, Brazil, 2020. A Kaplan-Meier survival estimates by age: <70 and ≥70 years. B. Kaplan-Meier survival estimates by not suggestive chest x-ray and suggestive. C.Kaplan-Meier survival estimates by nonwhite race and white race. D. Kaplan-Meier survival estimates by non-need of invasive MV (mechanical ventilation) and need of MV.









353

352

- Discussion 354
- 355

356 This work studies the mortality rates of patients with confirmed COVID-19 who were 357 admitted to a university hospital, a reference for the treatment of highly complex 358 conditions. The objective was to find the factors that are unique to this population

16

with different comorbidities, as well as the factors involved in greater severity andmortality from the disease.

361

The total mortality rate was 24.2% during hospitalization, with a 30-day mortality rate of 19.9%. Initial studies showed a mortality rate of 4.3% to 15% among patients hospitalized for SARS, [1,8], with more recent studies showing that it reaches 14% to 28% [3,12].

366

367 The data show a high median age (63 years) among patients hospitalized with 368 SARS and that those in the older age group have a higher mortality rate (43.1% in 369 those aged 70 years or over vs 15.5% in the others; RR=2.78; p<0.001). Initial 370 cohorts studied in China found median ages of 49 to 56 years among confirmed 371 and hospitalized cases of COVID-19, [1,8] although higher medians were also 372 found in later studies, such as a cohort study in New York that found a median age 373 of 63 years in patients with SARS [12]. Other studies have also shown higher 374 mortality rates in older age strata [2,12,13]. When stratified by the same age groups, 375 data from a multicenter study in New York found similar mortality rates (21% in-376 hospital mortality, with 42.83% aged 70 years or over vs 9.97% in other adults) [13]. 377 A Brazilian multicenter study, including patients from less complex hospitals, found 378 a mortality rate of 35.88% in patients aged 65 years or older vs 12.88% in the others 379 [14].

380

In this study's cohort, individuals had an average of 2.44 comorbidities before admission. This number is similar to that found in a subgroup of 355 patients in a report from Italy who died from COVID-19, where the average previous comorbidity was 2.7, [13] which reflects the previous clinical complexity of the patients included in this study. In particular, 95% of the individuals included in the present study had at least one previous comorbidity, with 23.6% having one, 27.9% having two, and

17

387 43.5% having at least 3 comorbidities. The Italian study showed a prevalence of 388 comorbidity of 25.1%, 25.6%, and 48.5%, respectively, in patients who died from 389 COVID-19 [13]. This reflects a greater previous clinical severity of patients treated 390 in a high complexity hospital, which proved to be in the spectrum of the highest 391 prevalence of comorbidities found in other studies. While there is a high prevalence 392 of classic non-communicable comorbidities in other cohorts, such as arterial 393 hypertension, obesity, and diabetes mellitus, [3,13,14] there was a high prevalence 394 of more complex conditions in this study, such as neoplasms, heart disease, and 395 immunosuppression, which are considered important factors for greater severity 396 and mortality [5,13].

397

398 Males corresponded to 49.7% of the cases, which is a risk factor for mortality 399 (33.8% vs 14.8%; RR=2.28; p=0.005). Males also account for a disproportionately 400 high number of critical cases and deaths in diverse cohorts worldwide [13,15-17]. 401 A Danish study showed a mortality rate among confirmed COVID-19 cases of 402 11.2% in males and 7.4% in females, with 47.1% of the individuals included being 403 male [16]. A meta-analysis using data from 90 studies from 46 different countries 404 totaling 3,111,714 individuals with a similar proportion of the sexes identified the 405 male sex as a risk factor for 2.84 times more intensive care admissions and 1.39 406 times greater mortality [17].

407

The black race (self-declared black or brown individuals) represented more than 90% of this cohort, in contrast with the proportions found in the Brazilian population, where in the 2019 National Household Sample Survey (in Portuguese: Pesquisa Nacional por Amostra de Domicílios - PNAD), 42.7% of Brazilians declared themselves as white, 46.8% as brown, 9.4% as black, and 1.1% as yellow or indigenous [18]. This percentage may reflect disparities in the social determinants of health in this population segment, as was found in other studies [19, 20], in

18

addition to highlighting social inequality in the Brazilian population. There is also a
tendency toward a higher mortality rate among whites (although without statistical
significance), with this group having a lower survival in the Cox model; however,
the small percentage of self-declared white patients limits the extrapolation of these
findings to the general population. Analyses controlled for comorbidities and
socioeconomic factors found no association between race and in-hospital COVID19 outcomes [21,22].

422

A median of 5 days of symptoms at the time of hospitalization was slightly lower than that found in other studies. Data suggest disease progression with mild symptoms in the first week [23]. One study showed a median of 5 days for the onset of dyspnea and 7 days for hospital admission [8]. Another study found a median of 8 days for the onset of dyspnea [1].

428

429 This study's data also draws attention to one of the difficulties in the management 430 of respiratory syndromes: the etiological diagnosis. Despite the collection being 431 done shortly after admission, the test results of swab exams take an average of 432 three days to be released. One study showed a mean time of 15.4 hours for RT-433 PCR results [12]. The delay in making the etiological diagnosis of pulmonary 434 conditions can lead to the unnecessary use of antimicrobials and their 435 consequences, as well as the need to use other more invasive forms of workup to 436 clarify the diagnosis [24].

437

The need for intensive care in 38% of hospitalized patients in this cohort was compatible with the end of greater severity reported in other studies, where it varied between 14% and 48%, but with a similar mortality rate [3,12,13,14]. The need for MV of 25.5% was also similar to findings described in other studies, varying between 12% and 33% [3,12,14], but this time with a higher mortality rate among

19

those requiring MV, which was 73% in our study compared to 60% in others [3].
The severity of the underlying health conditions in this cohort may have contributed
to its occurrence since the patients were being treated for serious diseases in a
high-complexity hospital. Despite not being statistically significant, the tendency for
those who survived to spend a longer amount of time on mechanical ventilation is
noteworthy, suggesting possible earlier death.

449

Having a chest X-ray taken – a simple, quick, and inexpensive procedure that can be easily interpreted by a radiologist – was of fundamental importance when COVID-19 was suspected (79.2% of the patients had a suggestive test), as well as for the outcome. The presence of about 20% of chest X-rays without any changes is consistent with what has been reported in the literature [25]. That there is such a readily performed test that predicts severity allows courses of treatment to be quickly implemented.

457

The most common findings on chest CTs were similar to those reported in other studies regarding the presence of ground glass opacities and septal thickening. Consolidations were slightly less common; pleural thickening and air bronchograms were much less frequently reported in this study's cohort. By contrast, the abundance of reports of pleural effusion and atelectasis, which may be associated with other comorbidities, becomes important [26].

464

Although other studies have linked an increase in D-dimer with mortality as it reflects the pro-coagulant changes associated with COVID-19 [3,8,27,28], this finding was not associated with higher mortality in this study, despite a small percentage of patients who had this test available during hospitalization. This may be explained by the fact that this test was performed only when there was a clinical indication or suspicion of pulmonary thromboembolism/deep venous thrombosis

20

471 (PTE/DVT) and not for the initial assessment of pro-coagulability in COVID-19.

472

The presence of lymphopenia was a common finding in most patients (58.4%). It
was also common in other studies, despite the variation in the total leukocyte count
[1, 29, 30].

476

477 A high RDW upon admission was not statistically significant as a risk factor for 478 mortality in this cohort (31.1% vs 21.7%; RR=1.43; p=0.413). However, this finding 479 was associated with higher mortality in the subgroup of patients aged 70 years and 480 over (66.7% vs 33.3%; RR=2; p= 0.029). Furthermore, a high RDW during 481 hospitalization after admission was a factor for mortality in the entire cohort (41.1%) 482 vs 10.2%; RR=4.03; p<0.001), and if all measurements are considered (admission 483 plus elevation), having a high RDW at any time during the hospital stay was 484 associated with higher mortality (39.7% vs 9.6%; RR=4.14; p<0.001). Some studies 485 have associated higher RDW values with critical forms and mortality from COVID-486 19. [31-36] This may explain why our study found an association between RDW 487 and mortality when age was stratified at such a high age (70 and over), where 488 critical forms may occur more frequently, but not over the entire spectrum of the 489 survival curve. In other words, the association was only true for higher ages. One 490 study of 1,641 patients found a relative mortality risk of 2.73 in patients with high 491 RDW upon admission as compared to those with normal RDW at that time. [9]

492

Factors that may contribute to this finding are the smaller number of patients included in the present study and the fact that there is a larger number of patients with cancer, who are known to have a better chance of having a previous change in the RDW. [37, 38] Recent studies have highlighted the prognostic value of RDW in both COVID-19 and cancer patients. In a prospective observational study, RDW was found to be a significant predictor of COVID-19 severity, with higher levels

21

499 associated with severe illness and acute kidney injury (AKI). Patients with elevated 500 RDW had increased odds of severe outcomes, emphasizing the need for routine 501 RDW assessment in COVID-19 patients. Another study from Massachusetts 502 General Hospital corroborated these findings, showing that an RDW greater than 503 14.5% at admission was linked to a significantly higher mortality risk, which 504 remained robust even after adjusting for various demographic and clinical factors. 505 Additionally, a further increase in RDW during hospitalization was associated with 506 a heightened mortality risk. These insights underline the utility of RDW as a valuable 507 biomarker for risk stratification and prognosis in both COVID-19 and cancer 508 contexts. [39-40]

509

510 There is a simple, available, fast, and inexpensive biomarker indicative of higher 511 mortality upon admission for the elderly as well as in disease progression for any 512 age group: a change in the RDW at any time increases mortality in relation to normal 513 measurements during hospitalization.

514

515 It is worth noting that these findings support considering RDW as a mortality factor 516 even when there is a high prevalence of previous comorbidities with high clinical 517 complexity. Even with the presence of factors for which this test may be changed 518 prior to infection (which could explain the lack of statistical significance for said 519 change as a risk factor for mortality at admission), this marker has a prognostic 520 value. The relevance of including it in the risk stratification of patients hospitalized 521 for COVID-19 is underscored, as is the fact that such an assessment ought to 522 consider the dynamics of these changes and not only admission statistics. It also 523 supports the use of a combination of risk factors (for example, age and RDW) in 524 predicting the risk of negative outcomes due to COVID-19.

525

526 To the best of our knowledge, no other study has evaluated this aspect for patients

22

527 of such clinical complexity for the Brazilian population. This is a single-center study 528 with a clinical profile and previous comorbidities different from those found in other 529 hospitals that do not provide treatment for complex cases, given that it is a 530 university hospital known to be a reference for such cases. The race variable might 531 interfere with hetero-identification instead of self-declaration upon admission. The 532 number of patients with cancer may interfere with RDW values, since such an exam 533 may already present altered values prior to SARS-CoV-2 infection in such patients. 534 In addition, several underlying acute and chronic diseases can change the RDW, 535 which could be a summary marker of the presence of such diseases associated 536 with unfavorable outcomes in COVID-19.

537

538 The study concludes that elevated RDW is a significant factor associated with 539 higher mortality in COVID-19 patients, particularly in those aged 70 years and older. 540 A high RDW during hospitalization is linked to increased mortality across the entire 541 cohort and having a high RDW at any point during the hospital stay correlates with 542 higher mortality rates. Additionally, age, male sex, radiographic changes, and 543 cardiovascular disease, which are already known severity and mortality factors, are 544 associated with higher intrahospital mortality from COVID-19. Further studies are 545 warranted to determine whether RDW alone can be used as a simple and available 546 biomarker for predicting COVID-19 mortality and to explore its relationship to the 547 pathophysiology of the disease.

548

549 Acknowledgement

550 We are deeply grateful to the patients who participated in this study and to the 551 healthcare workers who provided unwavering care and support.

552

553 Financial Disclosure or Funding

554 This research did not receive any specific grant from funding agencies in the public,

23

555 commercial, or not-for-profit sectors.

556

- 557 Conflict of Interest
- 558 The authors declare that there is no conflict of interest regarding the publication of
- 559 this paper.

560

561 Author Contributions

562 Dr. Helena Duani: Conceptualization, Methodology, Superv	/ision, Writing -
--	-------------------

563 original draft. Dr. Maderson Alvarez: Data curation, Formal analysis,

- 564 Visualization, Writing review & editing. Dr. Cecília Ravetti and Dr. Paula
- 565 Vassallo: Investigation, Resources, Project administration. Dr. Carla Jorge
- 566 <u>Machado</u>: Validation, Software, Writing review & editing.Dr. Vandack
- 567 Nobre and Milena Marcolino: Supervision, Project administration, Writing -
- 568 review & editing.
- 569 Data Availability
- 570 The data from this clinical study in the field of medicine are available upon request
- 571 to the authors, subject to prior evaluation.

- 573 Abbreviations and acronyms used in the manuscript:
- 574 COVID-19: Coronavirus Disease 2019
- 575 CT: computed tomography
- 576 HC-UFMG: Hospital das Clínicas of the Universidade Federal de Minas Gerais
- 577 HR: Hazard Ratio
- 578 ICU: Intensive Care Unit

- 579 MCV: mean corpuscular volume
- 580 MV: mechanical ventilation
- 581 PNAD: National Household Sample Survey, in Portuguese: Pesquisa Nacional por
- 582 Amostra de Domicílios
- 583 PTE/DVT: thromboembolism/deep venous thrombosis
- 584 RDW: Red blood cell distribution width
- **RR: Risk Ratio** 585
- 586 RT-PCR: real-time polymerase chain reaction
- 587 SARS: Severe Acute Respiratory Syndrome
- SD: standard deviation 588
- 589 SUS: Brazilian Unified Health System
- 590
- 591
- 592 REFERENCES
- 593
- 594 1. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 595 2019 China. The novel coronavirus in Wuhan, Lancet. 596 2020;395(10223):497-506.
- 597
- 598 2. Wu Z., McGoogan JM. Characteristics of and Important Lessons from the 599 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a 600 Report of 72314 Cases from the Chinese Center for Disease Control and 601 Prevention. JAMA - Journal of the American Medical Association.

602		2020;323(13):1239–42.
603 604	3.	Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of
605		adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
606		study. The Lancet. 2020;395(10229):1054–62.
607		
608	4.	Liang W., Guan W., Chen R., et al. Cancer patients in SARS-CoV-2
609		infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-
610		7.
611		
612	5.	Chow N., Fleming-Dutra K., Gierke R., et al. Preliminary Estimates of the
613		Prevalence of Selected Underlying Health Conditions Among Patients with
614		COVID-19 - US, February 12-March 28, 2020. MMWR Morb Mortal Wkly
615		<i>Rep</i> . 2020;69(13):382–6.
616		
617	6.	Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than
618		60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis.
619		2020;71(15):896–7. Mehra MR., Desai SS., Kuy S., Henry TD., Patel AN.
620		Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. New
621		England Journal of Medicine. 2020;382(25):e102.
622		
623	7.	Wang D., Hu B., Hu C., et al. Clinical Characteristics of 138 Hospitalized
624		Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
625		China. JAMA - Journal of the American Medical Association.
626		2020;323(11):1061–9.
627		
628	8.	Higgins JM., Foy BH., Carlson JCT., et al. Association of Red Blood Cell
629		Distribution Width with Mortality Risk in Hospitalized Adults with SARS-

26

630 CoV-2 Infection. *JAMA Netw Open*. 2020;3(9):1–13.

631

635

- 632 9. Chen N., Zhou M., Dong X., et al. Epidemiological and clinical
 633 characteristics of 99 cases of 2019 novel coronavirus pneumonia in
 634 Wuhan, China: a descriptive study. *The Lancet*. 2020;395(10223):507–13.
- 636 10. GBD 2021. Demographics Collaborators. Global age-sex-specific mortality,
 637 life expectancy, and population estimates in 204 countries and territories and
 638 811 subnational locations, 1950-2021, and the impact of the COVID-19
 639 pandemic: a comprehensive demographic analysis for the Global Burden of
 640 Disease Study 2021. *The Lancet.* 2024;403(10440):1989-2056.
- 642 11. Walker, J. L., Grint, D. J., Strongman, H., Eggo, R. M., Peppa, M., Minassian,
- C., Mansfield, K. E., Rentsch, C. T., Douglas, I. J., Mathur, R., Wong, A. Y.
 S., Quint, J. K., Andrews, N., Bernal, J. L., Scott, J. A., Ramsay, M., Smeeth,
- L., & McDonald, H. I. (2021). UK prevalence of underlying conditions which
 increase the risk of severe COVID-19 disease: a point prevalence study
 using electronic health records. *BMC public health.* 2021;21(1),484:1-14.
- 648
- 649 12. Onder G., Rezza G., Brusaferro S. Case-Fatality Rate and Characteristics
 650 of Patients Dying in Relation to COVID-19 in Italy. *JAMA Journal of the*651 *American Medical Association.* 2020;323(18):1775–6.
- 652
- 653 13. Williamson EJ., Walker AJ., Bhaskaran K., et al. Factors associated with
 654 COVID-19-related death using OpenSAFELY. *Nature.*655 2020;584(7821):430–6.
- 656
- 657 14. Chen T., Wu D., Chen H., et al. Clinical characteristics of 113 deceased
 658 patients with coronavirus disease 2019: Retrospective study. *The BMJ.*659 2020;368.

15. Kragholm K., Andersen MP., Gerds TA., et al. Association between Male

27

6	6	n
υ	υ	υ.

662	Sex and Outcomes of Coronavirus Disease 2019 (COVID-19)-A Danish
663	Nationwide, Register-based Study. Clinical Infectious Diseases.
664	2021;73(11):E4025–30.
665	
666	16. Peckham H., de Gruijter NM., Raine C., et al. Male sex identified by global
667	COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat
668	<i>Commun.</i> 2020;11(1):1–10.
669 670	17. IBGE. Características adicionais do mercado de trabalho 2019. 2020:12.
671 672	18. Price-Haywood EG., Burton J., Fort D., Seoane L. Hospitalization and
673	Mortality among Black Patients and White Patients with Covid-19. New
674	England Journal of Medicine. 2020;382(26):2534–43.
675 676	19. Mackey K., Ayers CK., Kondo KK., et al. Racial and ethnic disparities in
677	covid-19-related infections, hospitalizations, and deaths a systematic
678	review. Ann Intern Med. 2021;174(3):362–73.
679	
680	20. Moore J., Ricaldi J., Rose C., et al. Disparities in incidence of COVID-19
681	among underrepresented racial/ethnic groups in counties identified as
682	hotspots during June 5-18, 2020 - 22 States, February-June 2020. MMWR
683	Morb Mortal Wkly Rep. 2020;69(33):1122–6.
684	
685	21. Munõz-Price LS., Nattinger AB., Rivera F., et al. Racial Disparities in
686	Incidence and Outcomes among Patients with COVID-19. JAMA Netw
687	<i>Open.</i> 2020;3(9):1–12.
688	

28

689	22. Cohen PA., Hall LE., John JN., Rapoport AB. The Early Natural History of
690	SARS-CoV-2 Infection: Clinical Observations From an Urban, Ambulatory
691	COVID-19 Clinic. <i>Mayo Clin Proc</i> . 2020;95(6):1124–6.
692	
693	23. Khan S., Hasan SS., Bond SE., Conway BR., Aldeyab MA. Antimicrobial
694	consumption in patients with COVID-19: a systematic review and meta-
695	analysis. Expert Rev Anti Infect Ther. 2022;20(5):749–72.
696	
697	24. Wong HYF., Lam HYS., Fong AHT., et al. Frequency and Distribution of
698	Chest Radiographic Findings in Patients Positive for COVID-19.
699	Radiology. 2020;296(2):E72–8.
700	
701	25. Bao C., Liu X., Zhang H., Li Y., Liu J. Coronavirus Disease 2019 (COVID-
702	19) CT Findings: A Systematic Review and Meta-analysis. Journal of the
703	American College of Radiology. 2020;17(6):701–9.
704	
705	26.Wu C., Chen X., Cai Y., et al. Risk Factors Associated with Acute
706	Respiratory Distress Syndrome and Death in Patients with Coronavirus
707	Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med.
708	2020;180(7):934–43.
709	
710	27. Liao D., Zhou F., Luo L., et al. Haematological characteristics and risk
711	factors in the classification and prognosis evaluation of COVID-19: a
712	retrospective cohort study. Lancet Haematol. 2020;7(9):e671-8.
713	
714	28. Guan W., Ni Z., Hu Y., et al. Clinical Characteristics of Coronavirus
715	Disease 2019 in China. New England Journal of Medicine.

2020;382(18):1708-20.

717	
718	29. Parag Goyal JJC. Correspondence Clinical Characteristics of Covid-19 in
719	China. Clinical Characteristics of Covid-19 in China. 2020;100(1):1–3.
720	
721	30. Lee JJ., Montazerin SM., Jamil A., et al. Association between red blood
722	cell distribution width and mortality and severity among patients with
723	COVID-19: A systematic review and meta-analysis. J Med Virol.
724	2021;93(4):2513–22.
725	
726	31. Lippi G., Henry BM., Sanchis-Gomar F. Red Blood Cell Distribution Is a
727	Significant Predictor of Severe Illness in Coronavirus Disease 2019. Acta
728	Haematol. 2021;144(4):360–4.
729	
730	32. Lanini S., Montaldo C., Nicastri E., et al. COVID-19 disease - Temporal
731	analyses of complete blood count parameters over course of illness, and
732	relationship to patient demographics and management outcomes in
733	survivors and non-survivors: A longitudinal descriptive cohort study. PLoS
734	One. 2020;15(12 December):1–17.
735	
736	33. Zinellu A., Mangoni AA. Red blood cell distribution width, disease severity,
737	and mortality in hospitalized patients with SARS-CoV-2 infection: A
738	systematic review and meta-analysis. <i>J Clin Med.</i> 2021;10(2):1–11.
739	
740	34.Bommenahalli Gowda S., Gosavi S., Ananda Rao A., et al. Prognosis of
741	COVID-19: Red Cell Distribution Width, Platelet Distribution Width, and C-
742	Reactive Protein. Cureus. 2021; (February).
743	
744	35. Kaufmann CC., Ahmed A., Brunner U., et al. Red Cell Distribution Width

745	Upon Hospital Admission Predicts Short-Term Mortality in Hospitalized
746	Patients With COVID-19: A Single-Center Experience. Front Med
747	(Lausanne). 2021;8(3):1–9.
748	
749	36.Yağcı S., Serin E., Acicbe Ö., Zeren Mİ., Odabaşı MS. The relationship
750	between serum erythropoietin, hepcidin, and haptoglobin levels with
751	disease severity and other biochemical values in patients with COVID-19.
752	Int J Lab Hematol. 2021;43(S1):142–51.
753	
754	37. Patel HH., Patel HR., Higgins JM. Modulation of red blood cell population
755	dynamics is a fundamental homeostatic response to disease. Am J
756	<i>Hematol.</i> 2015;90(5):422–8.
757	
758	38. Chaudhury A., Miller GD., Eichner D., Higgins JM. Single-cell modeling of
759	routine clinical blood tests reveals transient dynamics of human response
760	to blood loss. <i>Elife.</i> 2019;8:1–12.
761	20 Hanny DM, Danait II, Danait C, Dubina C, Dannar DA, Olivara MUGd
/62	39. Henry BIN, Benoit JL, Benoit S, Pulvino C, Berger BA, Olivera MHSd,
763	Crutchfield CA, Lippi G. Red Blood Cell Distribution Width (RDW) Predicts
764	COVID-19 Severity: A Prospective, Observational Study from the
765	Cincinnati SARS-CoV-2 Emergency Department Cohort. Diagnostics.
766	2020; 10(9):618.
767 768	40. Foy BH, Carlson JCT, Reinertsen E, et al. Association of Red Blood Cell
769	Distribution Width with Mortality Risk in Hospitalized Adults With SARS-
770	CoV-2 Infection. JAMA Netw Open. 2020;3(9):e2022058.

771

772 Table 1: Main baseline characteristics, comorbidities, laboratory and radiological findings

773 of COVID-19 patients, survivor and non-survivors, in Belo Horizonte, Brazil, 2020.

		Total N=161 (100.0%)	Survivor N=122 (75.8%)	Death N=39 (24.2%)	P-value
Age	Mean (SD)	60.1 (16.9)	56.9 (16.7)	70.3 (13.3)	<0.001
Age >70 years [N (%)]	Yes	51 (31.7)	29 (56.9)	22 (43.1)	0.000
Sex [N (%)]	Male	80 (49.7)	53 (66.3)	27 (33.8)	0.005
Race/color [N (%)]	Black	147 (91.3)	114 (77.6)	33 (22.5)	0.089
Comorbidities [N (%)}	Mean (DP)	2.44 (1.4)	2.42 (1.4)	2.51 (1.5)	0.7184
BMI > 30 Kg/m2	Yes	20 (12.4)	18 (90)	2 (10)	0.163
Previous smoking	Yes	34 (21.1)	26 (76.5)	8 (23.5)	0.916
Current smoking	Yes	8 (5.0)	4 (50)	4(50)	0.098
Systemic Arterial Hypertension [N (%)]	Yes	74 (46.0)	54 (73)	20 (27)	0.444
Solid or hematological neoplasm [N (%)]	Yes	41 (25.5)	29 (70.7)	12 (29.3)	0.383
Diabetes mellitus [N (%)]	Yes	38 (23.6)	27 (71.1)	11 (29)	0.437
Chronic heart disease [N (%)]	Yes	35 (21.7)	22 (62.9)	13 (37.1)	0.044
Chronic lung disease [N (%)]	Yes	26 (16.1)	19 (73.1)	7 (26.9)	0.726
Chronic kidney disease [N (%)]	Yes	18 (11.2)	14 (77.8)	4 (22.2)	1.000
Solid organ transplant [N (%)]	Yes	12 (7.5)	10 (83.3)	2 (16.7)	0.732
Immunosuppression [N (%)]	Yes	71 (44.1)	52 (73.2)	19 (26.8)	0.505
Time of symptoms upon admission	Mean (DP)	6.07 (4.6)	6.4 (4.7)	5.2 (4.0)	0.1528
Time of symptoms until swab collection ¹	Mean (DP)	8.0 (5.3)	8.3 (5.2)	7.3 (5.6)	0.3006
Time of hospitalization until swab collection ¹	Mean (DP)	2.0 (4.0)	2.0 (3.8)	2.1 (4.5)	0.8162
Time until swab result ¹	Mean (DP)	3.1 (1.7)	3.1 (1.7)	3.4 (1.5)	0.2941
Hospitalization time ²	Mean (DP)	16.0 (12.9)	15.4 (12.7)	17.8 (13.6)	0.3185
Need for intensive care [N (%)]	Yes	62 (38.5)	30 (48.4)	32 (51.6)	0.000
Direct admission to ICU [N (%)]	Yes	34 (54.8)	18 (52.9)	16 (47.1)	0.429
ICU time	Mean (DP)	12.9 (14.3)	12.2 (17.3)	13.6 (11.2)	0.7194
Need for invasive mechanical ventilation [N (%)]	Yes	41 (25.5)	11 (26.8)	30 (73.2)	0.000
Invasive mechanical ventilation time	Mean (DP)	15.5 (19.3)	23.1 (32.7)	12.7 (10.6)	0.1275
Suggestive chest x-ray [N (%)] ³	Yes	114 (79.2)	79 (69.3)	35 (30.7)	0.022
Compatible chest CT [N (%)] ⁴	indeterminat e	8 (7.3)	6 (75)	2 (25)	0.512
	No	21 (19.1)	19 (90.5)	2 (9.5)	
	Yes	81 (73.6)	66 (81.5)	15 (18.5)	
Time of symptoms until CT	Mean (DP)	9.3 (5.7)	9.5 (5.7)	8.4 (5.9)	0.4478
Ground glass	Yes	91 (82.7)	73 (80.2)	18 (19.8)	0.186
Peripheral diffuse ground glass	Yes	81 (73.6)	64 (79)	17 (21)	0.149
Central diffused ground glass	Yes	2 (1.8)	2 (100)	0 (0.0)	1.000
Localized ground glass	Yes	10 (9.1)	9 (90)	1 (10)	1.000
Consolidation	Yes	39 (35.5)	29 (74.4)	10 (25.6)	0.085
Septal thickening	Yes	62 (56.4)	49 (79)	13 (21)	0.244
Bronchial thickening	Yes	7 (6.4)	7 (100)	0 (0)	0.602
Pleural thickening	Yes	4 (3.6)	2 (50)	2 (50)	0.137

Mosiac paving	Yes	20 (18.2)	11 (55)	9 (45)	0.000
Atelectasis	Yes	28 (25.5)	22 (78.6)	6 (21.4)	0.500
Pleural effusion	Yes	32 (29.1)	26 (81.3)	6 (18.8)	0.793
Lymphadenopathy	Yes	23 (20.9)	19 (82.6)	4 (17.4)	1.000
Air bronchogram	Yes	3 (2.7)	2 (66.7)	1 (33.3)	0.437
Pericardial effusion	Yes	9 (8.2)	8 (88.9)	1 (11.1)	1.000
Cardiomegaly	Yes	17 (15.5)	14 (82.4)	3 (17.7)	1.000
Nodule(s)	Yes	16 (14.5)	11 (68.8)	5 (31.3)	0.110
Micronodule(s)	Yes	12 (10.9)	10 (83.3)	2 (16.7)	1.000
Mass(es)	Yes	3 (2.7)	1 (33.3)	2 (66.7)	0.077
Pulmonary hypertension	Yes	12 (10.9)	10 (83.3)	2 (16.7)	1.000
Tree-in-bud	Yes	1 (0.9)	0 (0)	1 (100)	0.173
Bronchiectasis	Yes	6 (5.5)	6 (100)	0 (0)	0.587
Pulmonary infarction	Yes	3 (2.7)	2 (66.7)	1 (33.3)	0.437
Emphysema	Yes	9 (8.2)	7 (77.8)	2 (22.2)	0.652
Number of recovered blood counts	Mean (SD)	13.8 (12.9)	12.8 (12.9)	17 (12.5)	0.0778
RDW upon admission	Mean (SD)	14.5 (2.4)	14.4 (2.4)	14.9 (2.4)	0.2081
Leukocyte count upon admission	Mean (SD)	9.84 (25.0)	9.9 (28.5)	9.5 (6.6)	0.9320
Lymphocyte count upon admission	Mean (SD)	1.30 (2.0)	1.38 (2.1)	1.02 (1.1)	0.3374
Neutrophil count upon admission	Mean (SD)	6.20 (6.7)	5.9 (7.32)	7.0 (4.4)	0.4079
Platelet count upon admission	Mean (SD)	205.3 (105.6)	216.3 (110.7)	171.2 (80.0)	0.0198
VCM upon admission	Mean (SD)	86.6 (7.3)	86.6 (7.3)	86.6 (7.3)	0.9973
First D-dimer performed upon admission ⁵	Mean (SD)	2708 (4797)	2518(4063)	3418 (7114)	0.5857
RDW category	high	45 (28.0)	31 (68.9)	14 (31.1)	0.413
	normal	115 (71.4)	90 (78.3)	25 (21.7)	
	low	1 (0.6)	1 (100)	0 (0.0)	
RDW evolution	high	73 (45.3)	43 (58.9)	30 (41.1)	0.000
	normal	88 (54.7)	79 (89.8)	9 (10.2)	
Leukocyte Category	high	46 (28.6)	40 (87)	6 (13)	0.094
	normal	94 (58.4)	66 (70.2)	28 (29.8)	
	low	21 (13)	16 (76.2)	5 (23.8)	
Lymphocyte category	high	6 (3.7)	4 (66.7)	2 (33.3)	0.301
	normal	61 (37.9)	50 (82)	11 (18)	
	low	94 (58.4)	68 (72.3)	26 (27.7)	
Neutrophil category	high	108 (67.1)	77 (71.3)	31 (28.7)	0.197
	normal	40 (24.8)	34 (85)	6 (15)	
	low	13 (8.1)	11 (84.6)	2 (15.4)	
Platelet category	high	20 (12.4)	18 (90)	2 (10)	0.187
	normal	110 (68.3)	83 (75.5)	27 (24.6)	
	low	31 (19.3)	21 (67.7)	10 (32.3)	
VCM category	high	11 (6.8)	7 (63.6)	4 (36.4)	0.631
	normal	116 (72.1)	89 (76.7)	27 (23.3)	
	low	34 (21.1)	26 (76.5)	8 (23.5)	
D-dimer category ⁵	high	45 (28.0)	35 (77.8)	10 (22.2)	0.798
	na	109 (67.7)	81 (74.3)	28 (25.7)	
	normal	7 (4.3)	6 (85.7)	1 (14.3)	

33

- 4 patients underwent external swab before admission. For this variable: total 157, survivors 118, deaths 39. ² 1 patient remained hospitalized at the end of follow-up. For this variable: total 160, survivors 121, deaths 39.
- ³ 144 patients underwent chest X-ray. For this variable: total 144, survivors 106, deaths 38.
- ⁴ 110 patients underwent chest CT. For this variable: total 110, survivors 91, deaths 19.
- ⁵ 52 patients had D-dimer level registered. For this variable: total 52, survivors 41, deaths 11.

774

775

776 Table 2: Mortality risk according to age-stratified RDW category (normal or high) of COVID-

777 19 patients, in Belo Horizonte, Brazil, 2020.

Age group	Normal RDW during hospitalization		Higl ho	h RDW during spitalization	P-value	Risk ratio (95% CI)	
5.5.5	Ν	Mortality [n (%)]	Ν	Mortality [n (%)]			
<70	59	4 (6.8)	51	13 (25.5)	0.007	3.76 (1.31;10.8)	
70+	24	4 (16.7)	27	18 (66.7)	<0.001	4.00 (1.58;10.2)	
Total cohort	83	8 (9.6)	78	31 (39.7)	<0.001		
gross						4.12 (2.02; 8.41)	
Mantel- Haenszel Method						3.89 (1.93; 7.83)	
	Normal R	DW at admission	High RDW at admission		P- value	Dick ratio (05% CI)	
Age group	Ν	Mortality [n (%)]	Ν	Mortality [n (%)]	r-value		
<70	80	13 (16.3)	30	4 (13.3)	>0.999	0.82 (0.29;2.31)	
70+	36	12 (33.3)	15	10 (66.7)	0.029	2.00 (1.07;3.74)	
Total cohort	116	25 (21.6)	45	14 (31.1)	0.204		
gross						1.44 (0.82; 2.55)	
Mantel- Haenszel Method						1.41 (0.83; 2.39)	

778 779

780

781

782

783

784

- 786 Table 3 - Cox Model results and survival analysis of baseline characteristics, comorbidities,
- 787 laboratory and radiological findings of COVID-19 patients, survivor and non-survivors, in
- 788 Belo Horizonte, Brazil, 2020.

	Univariate		Multivariate	
Variable	HR (95% CI)	P-value	HR (95% CI)	P-value
Sex				
Female	1.00			
Male	2.3 (1.1;4.5)	0.018		
Age (in years)				
<70	1.0		1.00	
70+	3.3 (1.7;6.5)	<0.001	4.8 (2.3;10.3)	<0.001
Race/color				
Not white	1.0		1.00	
White	2.5 (1.0;6.1)	0.039	3.2 (1.2; 8.6)	0.018
Suggestive chest X-ray				
No	1.0		1.00	
Yes	3.2 (1.0;10.5)	0.052	3.5 (1.0;11.5)	0.044
Compatible chest CT				
No	1.0			
Yes	1.6 (0.7;3.6)	0.218		
Solid or hematological neoplasm				
No	1.0			
Yes	1.8 (0.9;3.7)	0.095		
Chronic heart disease				
No	1.0			
Yes	1.9 (1.0;3.8)	0.053		
Chronic lung disease				
No	1.0			
Yes	1.3 (0.6;2.9)	0.584		
Immunosuppression				
No	1.0			
Yes	1.6 (08;3.0)	0.173		
Leukocyte category				
Low	1.1 (0.4; 2.8)	0.892		
Normal	1.0			
High	0.5 (0.2; 1.1)	0.091		
Neutrophil category				
Low	0.7 (0.1;3.5)	0.647		
Normal	1.0			
High	1.6 (0.7;3.9)	0.287		
VCM category				
Low	0.8 (0.4; 1.9)	0.670		

Normal	1.0			
High	1.4 (0.5;3.9)	0.559		
Need for invasive MV				
No	1.0		1.00	
Yes	4.9 (2.2;10.6)	<0.001	3.8 (1.7;8.7)	0.001
Need for ICU				
No	1.0			
Yes	3.7 (1.6;8.6)	0.003		
High RDW while hospitalized				
No	1.0			
Yes	1.9 (0.9;4.1)	0.102		
High RDW upon admission or while				
hospitalized				
No	1.0			
Yes	1.9 (0.8;4.2)	0.133		